Targeting mTOR Signaling in Type 2 Diabetes Mellitus and Diabetes Complications

Area of Science:

• Cellular Biology
• Metabolic Diseases
• Endocrinology

Background:

• The mechanistic target of rapamycin (mTOR) is a key regulator of cellular metabolism and growth, operating through mTORC1 and mTORC2 complexes.
• mTOR integrates signals for energy, nutrients, and hormones to maintain metabolic homeostasis.
• Dysregulation of mTOR signaling is implicated in the pathology and complications of type 2 diabetes mellitus (T2DM).

Purpose of the Study:

• To review the current understanding of mTOR signaling's role in T2DM.
• To explore the involvement of mTOR in T2DM-associated end-organ complications.
• To discuss the therapeutic potential of mTOR inhibitors for T2DM treatment.

Main Methods:

• Literature review of studies on mTOR signaling pathways.
• Analysis of research linking mTORC1-S6K1 and mTORC2-AKT pathways to insulin sensitivity.
• Synthesis of evidence regarding mTOR's role in T2DM pathogenesis and complications.

Main Results:

• Aberrant mTOR signaling, particularly involving mTORC1-S6K1 and mTORC2-AKT, is linked to impaired insulin sensitivity in T2DM.
• mTOR pathway dysfunction contributes to the development of T2DM and its associated end-organ damage.
• Specific mTOR-mediated signaling schemes are critical for maintaining metabolic balance relevant to T2DM.

Conclusions:

• mTOR signaling pathways are central to the pathophysiology of T2DM.
• Targeting mTOR may offer a novel therapeutic strategy for managing T2DM and its complications.
• Further research into mTOR inhibitors is warranted for T2DM treatment.